Submission for OMB Review; Comment Request, 22819-22820 [2014-09344]
Download as PDF
<![CDATA[
22819
Federal Register / Vol. 79, No. 79 / Thursday, April 24, 2014 / Notices
issued in November 2009, encourages
federal agencies to take deliberate and
immediate action to eliminate fraud and
improper payments. As part of the
review of programs subsequent to this
executive order, HHS has determined
that additional information from each
administering agency is necessary to
assess grantee measures that are in place
to prevent, detect or address waste,
fraud and abuse in LIHEAP programs.
This Plan incorporates the data ACF
must report to HHS regarding program
integrity issues such as fraud prevention
controls.
On January 27, 2014, ACF published
a Federal Register Notice seeking 60
days of public comment on this
proposed information collection. One
state grantee provided comments. ACF
revised the Plan to address the
comments by ensuring that open field
boxes and attachment capability are
available if the answer choices are
insufficient to address the questions.
The revised model plan can be
viewed on the OCS Web site at:
https://www.acf.hhs.gov/programs/ocs/
programs/liheap.
Respondents: State, tribal and
territory governments.
AUNUAL BURDEN ESTIMATES
Number of
responses per
respondent
Plan (First year–FY 2015) .............................................................................
Plan (future years) .........................................................................................
Estimated Total Annual Burden
Hours: First year—420; Future years—
105.
Additional Information:
Copies of the proposed collection may
be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade SW., Washington, DC 20447,
Attn: ACF Reports Clearance Officer. All
requests should be identified by the title
of the information collection. Email
address: infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
Average burden
hours per
response
1
1
Number of
respondents
Instrument
2
0.50
210
210
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration for
Children and Families.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2014–09316 Filed 4–23–14; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Home Visiting: Approaches to
Father Engagement and Father’s
Experiences.
OMB No.: New Collection.
Description: The Administration for
Children and Families (ACF), U.S.
Total burden
hours
420
105
Department of Health and Human
Services (HHS), is proposing a data
collection activity as part of the Home
Visiting: Approaches to Father
Engagement and Father’s Experiences
study. This study will document
strategies used by selected home visiting
programs to engage and serve fathers
and the perceptions and experience of
participating fathers. The findings will
be of utility for many home visiting
programs that desire to increase the
active engagement of fathers to support
the positive development of children as
well as to organizations which provide
oversight and technical assistance to
home visiting programs. Through semistructured discussions, respondents will
be asked to comment on the most
important strategies to support and
facilitate fathers’ participation.
Respondents: Administrators and key
staff of selected home visiting programs,
home visitors, and selected participating
fathers and mothers.
ANNUAL BURDEN ESTIMATES
Total number
of respondents
Instrument
Number of
responses per
respondent
Average burden
hours per
response
Total burden
hours
Annual burden
hours
(rounded)
pmangrum on DSK3VPTVN1PROD with NOTICES
Guide for Selecting Parents for Interviews ......................
Interview Guide for Program Administrators ...................
Interview Guide for Home Visitors ...................................
Interview Guide for Fathers—English and Spanish
versions ........................................................................
Interview Guide for Mothers—English and Spanish
versions ........................................................................
Home Visit Observation Sheet ........................................
5
15
25
1
1
1
10
1.5
1.25
50
22.5
31.25
50
23
31
40
1
1.27
50.8
51
10
10
1
1
1.02
0.17
10.2
1.7
10
2
Estimated Total Annual Burden Hours .....................
........................
........................
..........................
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
VerDate Mar<15>2010
14:19 Apr 23, 2014
Jkt 232001
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: OPRE Reports
Clearance Officer. All requests should
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
..........................
167
be identified by the title of the
information collection. Email address:
OPREinfocollection@acf.hhs.gov.
E:\FR\FM\24APN1.SGM
24APN1
22820
Federal Register / Vol. 79, No. 79 / Thursday, April 24, 2014 / Notices
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration, for
Children and Families.
Karl Koerper,
OPRE Reports Clearance Officer.
[FR Doc. 2014–09344 Filed 4–23–14; 8:45 am]
BILLING CODE 4184–35–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
Use of Antihistamine Compounds for
the Treatment of Hepatitis C Virus
Description of Technology: The vast
majority of people infected with
Hepatitis C Virus (HCV) will have
chronic infection. Over decades, this
can lead to liver disease and liver
cancer. In fact, HCV infection is the
leading cause of liver transplants in the
VerDate Mar<15>2010
14:19 Apr 23, 2014
Jkt 232001
U.S. Several new drugs have recently
come into the market that will likely
change the HCV treatment paradigm.
However, the effectiveness of these new
drugs can vary depending on the HCV
genotype. Thus, there is still the need
for additional new therapeutics against
HCV.
The subject technology are small
molecule compounds identified using a
novel cell-based high throughput assay
of HCV infection. The compounds are
antihistamines that show potent
antiviral properties against HCV. One
advantage of these compounds is that
they are already on the market for the
treatment of allergic reactions and, thus,
have been used extensively in humans
and have excellent safety profiles with
known pharmaceutical properties. The
subject technology can also potentially
be used in combination with other HCV
therapeutics.
Potential Commercial Applications:
Prevention or treatment of HCV
infection.
Competitive Advantages: These
compounds are already on the market
and, thus, have known safety profiles
and pharmaceutical properties.
Development Stage
• Early-stage
• In vitro data available
Inventors: Jake Tsanyang Liang
(NIDDK), Juan Jose Marugan (NCATS),
Noel Terrance Southhall (NCATS), Xin
Hu (NCATS), Jingbo Xiao (NCATS),
Shanshan He (NIDDK), Marc Ferrer
(NCATS), Zongyi Hu (NIDDK), Wei
Zhang (NCATS)
Intellectual Property: HHS Reference
No. E–011–2014/0—US Provisional
Patent Application No. 61/909,414 filed
27 Nov 2013
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018; changke@
mail.nih.gov
Intranasal Nebulizer With Disposable
Drug Cartridge for Improved Delivery
of Vaccines and Therapeutics
Description of Technology: Intranasal
delivery is a simple, inexpensive and
needle-free route for administration of
vaccines and therapeutics. This
intranasal delivery technology,
developed with Creare LLC, includes
low-cost, disposable drug cartridges
(DDCs) that mate with a durable handheld device. The rechargeable-batterypowered device transmits ultrasonic
energy to the DDC to aerosolize the drug
and is capable of performing for eight
hours at 120 vaccinations per hour.
Potential applications for this platform
technology include intranasal
vaccination (e.g. seasonal or pandemic
influenza vaccines) and intranasal
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
delivery of locally active (e.g.
antihistamines, steroids) or systemically
active (e.g. pain medications, sedatives)
pharmaceuticals.
The DDCs themselves offer two
unique benefits. First, all components
that contact the active agent or the
patient may be easily disposed of,
which reduces the risk of patient crosscontamination and minimizes cleaning
and maintenance requirements of the
hand-held device. Second, DDCs
provide a low-cost and simple method
to package and distribute individual
doses.
This technology also allows for
significant dose-sparing. Preliminary
studies have shown robust immune
responses when this technology is used
to delivery significantly reduced doses
of Live Attenuated Influenza Vaccine in
animal models. The intranasal nebulizer
produces droplets sized for optimum
depositioning in the nasal airway. The
small nebulizer droplets essentially
‘‘spray paint’’ the internal nasal airway,
resulting in an increased tissue surface
coverage that may enable a significant
dose reduction. In contrast, currently
available nasal delivery devices, such as
nasal sprays and droppers, do not
provide efficient intranasal delivery in
humans because the large droplets they
generate fail to coat a significant portion
of the nasal airway. Large droplets also
tend to drip out of the nose or down the
throat, which can be unpleasant for the
patient in addition to wasting a sizable
portion of the active agent.
Potential Commercial Applications
• Intranasal delivery of vaccines and
therapeutics
• Childhood vaccination programs,
mass immunization campaigns, or
response to epidemics
Competitive Advantages
• Safe, needle-less delivery
• No patient-to-patient contamination
• Long-life, rechargeable battery
• Consistent delivery and dose-sparing
• Nasal delivery of live-attenuated
vaccines may be more effective than
traditional injected vaccines
• Cost-effective
• Reduces biohazard waste
• May be administered by personnel
with minimal medical training
• Easy means of delivery to children
with fear of needles
Development Stage
• Prototype
• In vitro data available
• In vivo data available (animal)
Inventors: Mark J. Papania (CDC), et
al.
Publication: Smith JH, et al.
Nebulized live-attenuated influenza
E:\FR\FM\24APN1.SGM
24APN1
]]>Agencies
[Federal Register Volume 79, Number 79 (Thursday, April 24, 2014)]
[Notices]
[Pages 22819-22820]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09344]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Submission for OMB Review; Comment Request
Title: Home Visiting: Approaches to Father Engagement and Father's
Experiences.
OMB No.: New Collection.
Description: The Administration for Children and Families (ACF),
U.S. Department of Health and Human Services (HHS), is proposing a data
collection activity as part of the Home Visiting: Approaches to Father
Engagement and Father's Experiences study. This study will document
strategies used by selected home visiting programs to engage and serve
fathers and the perceptions and experience of participating fathers.
The findings will be of utility for many home visiting programs that
desire to increase the active engagement of fathers to support the
positive development of children as well as to organizations which
provide oversight and technical assistance to home visiting programs.
Through semi-structured discussions, respondents will be asked to
comment on the most important strategies to support and facilitate
fathers' participation.
Respondents: Administrators and key staff of selected home visiting
programs, home visitors, and selected participating fathers and
mothers.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Number of Average burden Annual burden
Instrument Total number responses per hours per Total burden hours
of respondents respondent response hours (rounded)
----------------------------------------------------------------------------------------------------------------
Guide for Selecting Parents for 5 1 10 50 50
Interviews.....................
Interview Guide for Program 15 1 1.5 22.5 23
Administrators.................
Interview Guide for Home 25 1 1.25 31.25 31
Visitors.......................
Interview Guide for Fathers-- 40 1 1.27 50.8 51
English and Spanish versions...
Interview Guide for Mothers-- 10 1 1.02 10.2 10
English and Spanish versions...
Home Visit Observation Sheet.... 10 1 0.17 1.7 2
-------------------------------------------------------------------------------
Estimated Total Annual .............. .............. .............. .............. 167
Burden Hours...............
----------------------------------------------------------------------------------------------------------------
Additional Information: Copies of the proposed collection may be
obtained by writing to the Administration for Children and Families,
Office of Planning, Research and Evaluation, 370 L'Enfant Promenade
SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. All
requests should be identified by the title of the information
collection. Email address: OPREinfocollection@acf.hhs.gov.
[[Page 22820]]
OMB Comment: OMB is required to make a decision concerning the
collection of information between 30 and 60 days after publication of
this document in the Federal Register. Therefore, a comment is best
assured of having its full effect if OMB receives it within 30 days of
publication. Written comments and recommendations for the proposed
information collection should be sent directly to the following: Office
of Management and Budget, Paperwork Reduction Project, Email: OIRA_SUBMISSION@OMB.EOP.GOV, Attn: Desk Officer for the Administration, for
Children and Families.
Karl Koerper,
OPRE Reports Clearance Officer.
[FR Doc. 2014-09344 Filed 4-23-14; 8:45 am]
BILLING CODE 4184-35-P
